KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardlytics (CDLX) Current Deferred Revenue (2017 - 2025)

Cardlytics' Current Deferred Revenue history spans 9 years, with the latest figure at $2.6 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 20.19% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $2.6 million, up 20.19%, while the annual FY2025 figure was $2.6 million, 20.19% up from the prior year.
  • Current Deferred Revenue reached $2.6 million in Q4 2025 per CDLX's latest filing, down from $3.4 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $4.7 million in Q2 2022 to a low of $259000.0 in Q1 2021.
  • Average Current Deferred Revenue over 5 years is $2.6 million, with a median of $2.7 million recorded in 2023.
  • Peak YoY movement for Current Deferred Revenue: plummeted 57.05% in 2021, then surged 1105.41% in 2022.
  • A 5-year view of Current Deferred Revenue shows it stood at $3.3 million in 2021, then tumbled by 46.62% to $1.8 million in 2022, then surged by 37.35% to $2.4 million in 2023, then dropped by 10.44% to $2.2 million in 2024, then rose by 20.19% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for CDLX's Current Deferred Revenue are $2.6 million (Q4 2025), $3.4 million (Q3 2025), and $3.1 million (Q2 2025).